Pulmonology (Sep 2021)

Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort

  • S. Koirala,
  • S. Borisov,
  • E. Danila,
  • A. Mariandyshev,
  • B. Shrestha,
  • N. Lukhele,
  • M. Dalcolmo,
  • S.R. Shakya,
  • S. Miliauskas,
  • L. Kuksa,
  • S. Manga,
  • A. Aleksa,
  • J.T. Denholm,
  • H.B. Khadka,
  • A. Skrahina,
  • S. Diktanas,
  • M. Ferrarese,
  • J. Bruchfeld,
  • A. Koleva,
  • A. Piubello,
  • G.S. Koirala,
  • Z.F. Udwadia,
  • D.J. Palmero,
  • M. Munoz-Torrico,
  • R. GC,
  • G. Gualano,
  • V.I. Grecu,
  • I. Motta,
  • A. Papavasileiou,
  • Y. Li,
  • W. Hoefsloot,
  • H. Kunst,
  • J. Mazza-Stalder,
  • M.-C. Payen,
  • O.W. Akkerman,
  • E. Bernal,
  • V. Manfrin,
  • A. Matteelli,
  • H. Mustafa Hamdan,
  • M. Nieto Marcos,
  • J. Cadiñanos Loidi,
  • J.J. Cebrian Gallardo,
  • R. Duarte,
  • N. Escobar Salinas,
  • R. Gomez Rosso,
  • R. Laniado-Laborín,
  • E. Martínez Robles,
  • S. Quirós Fernandez,
  • A. Rendon,
  • I. Solovic,
  • M. Tadolini,
  • P. Viggiani,
  • E. Belilovski,
  • M.J. Boeree,
  • Q. Cai,
  • E. Davidavičienė,
  • L.D. Forsman,
  • J. De Los Rios,
  • J. Drakšienė,
  • A. Duga,
  • S.E. Elamin,
  • A. Filippov,
  • A. Garcia,
  • I. Gaudiesiute,
  • B. Gavazova,
  • R. Gayoso,
  • V. Gruslys,
  • J. Jonsson,
  • E. Khimova,
  • G. Madonsela,
  • C. Magis-Escurra,
  • V. Marchese,
  • M. Matei,
  • C. Moschos,
  • B. Nakčerienė,
  • L. Nicod,
  • F. Palmieri,
  • A. Pontarelli,
  • A. Šmite,
  • M.B. Souleymane,
  • M. Vescovo,
  • R. Zablockis,
  • D. Zhurkin,
  • J.-W. Alffenaar,
  • J.A. Caminero,
  • L.R. Codecasa,
  • J.-M. García-García,
  • S. Esposito,
  • L. Saderi,
  • A. Spanevello,
  • D. Visca,
  • S. Tiberi,
  • E. Pontali,
  • R. Centis,
  • L. D'Ambrosio,
  • M. van den Boom,
  • G. Sotgiu,
  • G.B. Migliori

Journal volume & issue
Vol. 27, no. 5
pp. 403 – 412

Abstract

Read online

The World Health Organization (WHO) recommends countries introduce new anti-TB drugs in the treatment of multidrug-resistant tuberculosis.The aim of the study is to prospectively evaluate the effectiveness of bedaquiline (and/or delamanid)- containing regimens in a large cohort of consecutive TB patients treated globally.This observational, prospective study is based on data collected and provided by Global Tuberculosis Network (GTN) centres and analysed twice a year.All consecutive patients (including children/adolescents) treated with bedaquiline and/or delamanid were enrolled, and managed according to WHO and national guidelines.Overall, 52 centres from 29 countries/regions in all continents reported 883 patients as of January 31st 2021, 24/29 countries/regions providing data on 100% of their consecutive patients (10–80% in the remaining 5 countries).The drug-resistance pattern of the patients was severe (>30% with extensively drug-resistant -TB; median number of resistant drugs 5 (3−7) in the overall cohort and 6 (4−8) among patients with a final outcome).For the patients with a final outcome (477/883, 54.0%) the median (IQR) number of months of anti-TB treatment was 18 (13−23) (in days 553 (385–678)). The proportion of patients achieving sputum smear and culture conversion ranged from 93.4% and 92.8% respectively (whole cohort) to 89.3% and 88.8% respectively (patients with a final outcome), a median (IQR) time to sputum smear and culture conversion of 58 (30−90) days for the whole cohort and 60 (30−100) for patients with a final outcome and, respectively, of 55 (30−90) and 60 (30−90) days for culture conversion.Of 383 patients treated with bedaquiline but not delamanid, 284 (74.2%) achieved treatment success, while 25 (6.5%) died, 11 (2.9%) failed and 63 (16.5%) were lost to follow-up.

Keywords